Therapy interrupted: FDA reporting patterns
68,083 FDA FAERS reports mention Therapy interrupted. 29,745 reports have a serious outcome flag.
Medicines named as suspect
- Adalimumab: 6,228 reports
- Etanercept: 3,884 reports
- Relugolix: 3,831 reports
- Lenalidomide: 3,612 reports
- Certolizumab Pegol: 3,536 reports
- Abatacept: 1,922 reports
- Upadacitinib: 1,801 reports
- Clozapine: 1,780 reports
- Amikacin: 1,401 reports
- Tofacitinib: 1,208 reports
- Secukinumab: 1,088 reports
- Rifaximin: 1,083 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.